Online citations, reference lists, and bibliographies.

Association Of Prothrombin Complex Concentrate Administration And Hematoma Enlargement In Non–vitamin K Antagonist Oral Anticoagulant–related Intracerebral Hemorrhage

S. Gerner, J. Kuramatsu, J. Sembill, M. Sprügel, M. Endres, K. Haeusler, P. Vajkoczy, P. Ringleb, J. Purrucker, T. Rizos, F. Erbguth, P. Schellinger, G. Fink, H. Stetefeld, H. Schneider, H. Neugebauer, J. Roether, J. Classen, D. Michalski, A. Doerfler, S. Schwab, H. Huttner
Published 2018 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
To investigate parameters associated with hematoma enlargement in non–vitamin K antagonist oral anticoagulant (NOAC)‐related intracerebral hemorrhage (ICH).
This paper references
10.1001/jamaneurol.2015.3884
Emergency Reversal of Novel Oral Anticoagulants: Help Is on the Way.
S. Mayer (2016)
10.1161/STROKEAHA.116.013326
Degree and Timing of Intensive Blood Pressure Lowering on Hematoma Growth in Intracerebral Hemorrhage: Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial-2 Results
C. Carcel (2016)
10.1007/s12028-015-0213-y
The Role of FEIBA in Reversing Novel Oral Anticoagulants in Intracerebral Hemorrhage
Jamil R. Dibu (2015)
10.1016/S0140-6736(16)32410-2
Thrombolytic removal of intraventricular haemorrhage in treatment of severe stroke: results of the randomised, multicentre, multiregion, placebo-controlled CLEAR III trial
D. Hanley (2017)
10.1186/cc12685
Management of bleeding and coagulopathy following major trauma: an updated European guideline
D. Spahn (2013)
10.1056/NEJMoa1502000
Idarucizumab for Dabigatran Reversal.
C. Pollack (2015)
10.1016/j.jacc.2014.05.065
Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants.
A. Cuker (2014)
10.1001/jamaneurol.2015.3682
Early Clinical and Radiological Course, Management, and Outcome of Intracerebral Hemorrhage Related to New Oral Anticoagulants.
J. Purrucker (2016)
10.1160/TH12-05-0319
New direct oral anticoagulants--current therapeutic options and treatment recommendations for bleeding complications.
W. Miesbach (2012)
10.1016/S1474-4422(16)00110-1
Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial
T. Steiner (2016)
10.1016/S1474-4422(16)30008-4
Rapid reversal of haematoma expansion associated with vitamin K antagonists
J. Eikelboom (2016)
10.1253/circj.CJ-14-0909
Reversal of rivaroxaban-induced alterations on hemostasis by different coagulation factor concentrates – in vitro studies with steady and circulating human blood.
G. Escolar (2015)
10.1212/01.WNL.0000138428.40673.83
Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage
J. J. Flibotte (2004)
10.1016/S0140-6736(13)62343-0
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
C. Ruff (2014)
10.1177/0962280206074463
Multiple imputation of discrete and continuous data by fully conditional specification
S. van Buuren (2007)
10.1056/NEJMoa1603460
Intensive Blood-Pressure Lowering in Patients with Acute Cerebral Hemorrhage.
A. Qureshi (2016)
Intensive bloodpressure lowering in patients with acute cerebral hemorrhage
AI Qureshi (2016)
10.1016/j.jvs.2016.11.019
Andexanet Alfa for Acute Major Bleeding Associated With Factor Xa Inhibitors
S. Connolly (2017)
10.1160/TH11-01-0052
Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis.
F. Dentali (2011)
10.1182/blood-2013-09-529784
How I treat target-specific oral anticoagulant-associated bleeding.
D. Siegal (2014)
10.1161/CIR.0000000000000477
Management of Patients on Non–Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association
A. Raval (2017)
10.1007/s12028-015-0222-x
Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage
J. Frontera (2015)
10.1161/CIRCULATIONAHA.111.029017
Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects
E. Eerenberg (2011)
10.1161/STROKEAHA.114.006661
Characteristics of Intracerebral Hemorrhage During Rivaroxaban Treatment: Comparison With Those During Warfarin
Joji Hagii (2014)
10.1080/01621459.1988.10478722
A Test of Missing Completely at Random for Multivariate Data with Missing Values
R. Little (1988)
10.1161/01.STR.28.1.1
Early hemorrhage growth in patients with intracerebral hemorrhage.
T. Brott (1997)
10.1212/WNL.0000000000002310
Volume and functional outcome of intracerebral hemorrhage according to oral anticoagulant type
D. Wilson (2016)
10.1161/STR.0b013e3181ec611b
Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association
L. Morgenstern (2010)
10.1056/NEJMra1206531
Management of antithrombotic therapy in patients undergoing invasive procedures.
T. Baron (2013)
10.1093/europace/euv309
Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation.
H. Heidbuchel (2015)
Idarucizumab for dabigatran reversal
Anna D. Garrett (2015)
10.1136/jnnp-2016-315346
Intensive blood pressure lowering in patients with acute intracerebral haemorrhage: clinical outcomes and haemorrhage expansion. Systematic review and meta-analysis of randomised trials
G. Boulouis (2017)
10.1097/MBC.0b013e32834f1b0c
Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran
J. Stangier (2012)
10.1093/europace/eut083
European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation.
H. Heidbuchel (2013)
10.1111/jth.12949
Reversal of oral factor Xa inhibitors by prothrombin complex concentrates: a re‐appraisal
W. Dzik (2015)
10.1093/eurheartj/ehs408
Acute management of bleeding in patients on novel oral anticoagulants.
D. Siegal (2013)
10.1161/STROKEAHA.108.520668
Hematoma Growth in Oral Anticoagulant Related Intracerebral Hemorrhage
B. Cucchiara (2008)
10.1016/S1474-4422(06)70495-1
Clinical interpretation and use of stroke scales
S. Kasner (2006)
10.1056/NEJMc1411800
Use of PER977 to reverse the anticoagulant effect of edoxaban.
J. Ansell (2014)
10.1001/jama.2015.0846
Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage.
J. Kuramatsu (2015)
Warfarin-related intraventricular hemorrhage: imaging and outcome
A Biffi (2011)



This paper is referenced by
10.1161/STROKEAHA.118.021614
Antiplatelet Therapy in Primary Spontaneous and Oral Anticoagulation–Associated Intracerebral Hemorrhage
M. Sprügel (2018)
10.1055/A-0657-7643
Blutdruckmanagement beim akuten Schlaganfall (Ischämie, Blutung, SAB)
J. Kuramatsu (2018)
10.1161/STROKEAHA.118.023492
Characteristics in Non-Vitamin K Antagonist Oral Anticoagulant-Related Intracerebral Hemorrhage.
S. Gerner (2019)
10.1016/j.tcm.2019.03.004
A review of reversal of oral anticoagulants, old and new, in major bleeding and the need for urgent surgery.
Truman John Milling (2019)
10.1111/bjh.15705
Efficacy and safety of prothrombin complex concentrate in patients treated with rivaroxaban or apixaban compared to warfarin presenting with major bleeding
D. Arachchillage (2019)
10.1007/s00101-018-0474-x
Intensivmedizinische Studien aus 2017/2018
C. J. Reuß (2018)
10.1159/000492395
Peak Troponin I Levels Are Associated with Functional Outcome in Intracerebral Hemorrhage
S. Gerner (2018)
10.1016/j.ajem.2019.12.008
Real-world utilization of andexanet alfa.
C. S. Brown (2019)
10.1055/s-0038-1675816
The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations.
R. De Caterina (2019)
10.1055/A-0829-8928
Neues beim Schlaganfall unter besonderer Berücksichtigung älterer Patienten
Hans Christoph Diener (2019)
10.1002/acn3.51001
Hematoma enlargement characteristics in deep versus lobar intracerebral hemorrhage
J. Sembill (2020)
Stroke Prevention and Treatment: New Insights into NOACs and Reversal
(2018)
10.5603/CJ.2018.0080
Use of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation - Messages from the 2018 EHRA.
A. Tomaszuk-Kazberuk (2018)
10.1007/s12028-020-00968-6
Efficacy of 4-Factor Prothrombin Complex Concentrates in Factor Xa Inhibitor-Associated Intracranial Bleeding
Matthew J. Korobey (2020)
10.1016/j.jocn.2018.11.032
Outcomes of intraparenchymal hemorrhage after direct oral anticoagulant or vitamin K antagonist therapy: A systematic review and meta-analysis
Aislyn C. DiRisio (2019)
10.1016/j.nec.2018.06.007
Management of Intraoperative Coagulopathy.
M. Bar-Natan (2018)
10.1136/jnnp-2018-319786
Heparin for prophylaxis of venous thromboembolism in intracerebral haemorrhage
M. Sprügel (2019)
10.1182/bloodadvances.2018024893
American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy.
D. Witt (2018)
10.1177/1747493019828555
Management of oral anticoagulation after intracerebral hemorrhage
J. Kuramatsu (2019)
10.1007/s00059-019-4802-y
Management von intrazerebralen Blutungen unter oraler Antikoagulation
J. Sembill (2019)
10.1007/978-3-030-22445-5
Case Studies in Emergency Medicine: LEARNing Rounds: Learn, Evaluate, Adopt, Right Now
Colin G. Kaide (2020)
10.1177/1747493019895662
Age-dependent clinical outcomes in primary versus oral anticoagulation-related intracerebral hemorrhage.
M. Sprügel (2019)
10.1177/1747493019895654
Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany—Updated series of 120 cases
Pawel Kermer (2020)
10.1007/s00068-019-01233-y
Idarucizumab in major trauma patients: a single centre real life experience
D. Oberladstaetter (2019)
10.1097/ALN.0000000000002910
Four-factor Prothrombin Complex Concentrate for the Management of Patients Receiving Direct Oral Activated Factor X Inhibitors.
Oliver Grottke (2019)
10.1007/s11239-020-02154-z
Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products
Renée Del Castillo (2020)
10.1007/s15005-018-2629-3
Prothrombinkomplex hält das Größenwachstum der Blutung nicht auf
H. -C Diener (2018)
10.1186/s42466-019-0018-0
Resumption of oral anticoagulation after spontaneous intracerebral hemorrhage
J. Sembill (2019)
10.1007/s00415-020-09775-7
A review of anticoagulation in patients with central nervous system malignancy: between a rock and a hard place
Dawn Swan (2020)
10.1016/j.hest.2020.01.001
Anticoagulant-associated intracerebral hemorrhage
Andrea Morotti (2020)
10.1007/s13311-020-00902-w
Advances in Therapeutic Approaches for Spontaneous Intracerebral Hemorrhage
Mais N. Al-Kawaz (2020)
10.1007/s11910-019-0954-7
Patients on NOACs in the Emergency Room
Stefan T. Gerner (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar